Item 8.01 Other Events.

On January 8, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing positive longer-term safety and efficacy data from the first three cohorts of the Company's ongoing Phase 1/2 studies of DTX401 an investigational adeno-associated virus ("AAV") gene therapy for the treatment of Glycogen Storage Disease Type Ia (GSDIa), and DTX301, an AAV gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency, and other updates related to the Company's gene therapy portfolio.

A copy of the Press Release is filed as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



Exhibit No. Description
99.1          Press Release, dated January 8, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 8, 2021 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses